Related people
Andrew Payne
Andrew is a senior associate in the intellectual property team and provides advice on contentious and non-contentious patent issues. He has a particular interest in advising life sciences companies, following a previous career as a medicinal chemist in the pharmaceutical industry.
Show full CV
Hide full CV
More
Show less
More
Show less
Career
| Since 2020 | Senior Associate, Taylor Wessing |
| 2015 - 2020 | Associate, Taylor Wessing |
| 2013 - 2015 | Trainee Solicitor , CMS Cameron McKenna |
| 2009 - 2013 | Group Leader, Medicinal Chemistry at Eisai |
| 2000 - 2009 | Team Leader, GlaxoSmithKline |
| 1998 - 1999 | Postdoctoral Researcher, The University of Texas at Austin |
Education
| 2015 | Admitted as a lawyer, England & Wales |
| 2013 | LPC distinction, BPP Law School |
| 2011 | GDL commendation, BPP Law School, London |
| 1997 | PhD in synthetic organic chemistry from Imperial College, London |
| 1994 | BSc Hons Chemistry, Imperial College and Università degli Studi di Firenze, Italy |
Publications
Declaratory Relief in the English Patents Court, Bio-Science Law Review, 2016, p 123-128 |
Additional languages
| English |
Latest news & insights
Patents & innovation
Click here to find out more
Dealing with difficult service in the UPC: The cases of Philips IP Ventures v Belkin and Panasonic v Xiaomi as examples.
24 January 2024
In-depth analysis
by multiple authors
Life sciences & healthcare
Click here to find out more
Brexit and beyond – Wellcome's recommendations from the Future Partnership Project
30 March 2018
Briefing
by Andrew Payne
Life sciences & healthcare
Click here to find out more
Licence held to be exclusive despite option
28 February 2018
Briefing
by Andrew Payne
Synapse
Click here to find out more
Data exclusivity for innovators - a bridge too far?
1 September 2016
QUICK READ
by Andrew Payne